Earlier this year, Senseonics announced it had entered into a distribution partnership with Geo-Med, LLC — verified Service-Disabled Veteran-Owned Small Business — to provide veterans with diabetes access to the Eversense implantable continuous glucose monitor (CGM).

With this distribution partnership, Senseonics marks its entry into the Veterans Health Administration (VHA), which serves roughly nine million veterans, as well as several other federal-administered health care programs. A 2017 study by a team of Tennessee researchers found that diabetes was more prevalent among veterans than among the general population; the researchers estimated that 25 percent (2.25 million) of veterans within the VHA have diabetes. The data did not distinguish between type 1 diabetes and type 2 diabetes in that figure.

According to Mike Gill, Senseonics U.S. vice-president of operations, the partnership has the potential to keep costs down for the VHA because the Eversense CGM is procured directly  through its prosthetics division, rather than through a pharmacy.

At least one Veterans Affairs medical center has begun offering the CGM to veterans with diabetes already. In a phone interview with T1D Exchange Glu, Gill relayed two instances in which veterans with diabetes with type 1 diabetes benefitted from the option of the Eversense CGM — one who benefitted from the feature of on-skin vibration alarms because he worked in a noisy construction site and another who sweated too much at work as a tree trimmer to be able to keep on a traditional CGM sensor. Gill said that Senseonics offers an important CGM option for a population who may have some unique challenges. Unlike with other CGMs, the sensor is implanted into the skin, which means using the system requires less maintenance and there is less chance for accidental detachments.

Read Full Article Here